At what stage does pancreas allograft rejection become irreversible?: an experimental study.

BACKGROUND It is commonly believed that abnormal blood glucose levels indicate irreversible rejection. We were interested in determining the stage at which rejection remains reversible. METHODS A total of 54 Lewis rats were rendered diabetic with 55 mg/kg streptozocin and were then given a pancreas transplant from Brown Norway donors. Pancreatic juice was collected in a subcutaneous reservoir. All recipients received 15 mg/kg cyclosporine A (CsA) for 5 days. CsA was then discontinued for 2 days (n=7, group 1), 4 days (n=7, group 2), 6 days (n=9, group 3), 8 days (n=9, group 4), 9 days (n=11, group 5), and 10 days (n=11, group 6). Two animals of each group were euthanized at the end of the immunosuppressive-free interval, for histological assessment of the grade of rejection (G0, GI, GII, GIII). Rejection was treated with methylprednisolone (7 mg/kg body weight) and CsA (15 mg/kg body weight). The volume of pancreatic juice, together with juice cytology (C0, CI, CII) and blood glucose levels, was assessed daily. RESULTS Blood glucose remained normal throughout the observation period in animals with GI and GII rejection. The numbers of animals that became diabetic were as follows: 5 of 9 (group 4), 7 of 11 (group 5), and 8 of 11 (group 6). Decreased amounts of pancreatic juice were observed in all animals, except those in group 1. The histology returned to normal after anti-rejection therapy in four animals (57%) of group 1, in two animals (28%) of group 2, and in one animal (11%) of groups 3 and 4, respectively. Although there was no animal in groups 5 and 6 with normal graft histology after treatment, there were still four (36%) and three (27%) animals, respectively, that were normoglycemic and that had pancreatic grafts with well-preserved islets. CONCLUSIONS From these data, we conclude that even GIII rejection with severe endothelialitis and isleitis can be reversed. Therefore, we suggest that a trial of enhanced immunosuppression is justified in patients with advanced pancreas allograft rejection.

[1]  G. Tydén,et al.  Triple versus quadruple induction immunosuppression in pancreas transplantation. , 1995, Transplantation proceedings.

[2]  G. Tydén,et al.  Serum levels of pancreatic amylase and pancreas-specific protein as markers of pancreatic graft rejection episodes. , 1995, Transplantation proceedings.

[3]  P. Landais,et al.  Survival modelling in kidney transplantation: hazard rates of graft loss. Transplant Working Group of the Registry Committee of the European Dialysis and Transplantation Association-European Renal Association (EDTA-ERA). , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  N. Senninger,et al.  Albuminuria as an indicator of rejection in bladder-drained pancreas allografts. , 1994, Transplantation.

[5]  M. Nieminen,et al.  Frequency of infections and their relation to episodes of acute rejection among heart allograft recipients. , 1994, Presse medicale.

[6]  M. Henry,et al.  The frequency of rejection episodes after combined kidney-pancreas transplant--the impact on graft survival. , 1994, Transplantation.

[7]  R. Stratta,et al.  Histologic confirmation of acute rejection detected by urine cytology in pancreas transplant recipients. , 1994, Transplantation proceedings.

[8]  M. Abecassis,et al.  Markers for pancreatic allograft rejection: comparison of serum anodal trypsinogen, serum amylase, serum creatinine and urinary amylase. , 1994, Clinical transplantation.

[9]  L. Miller,et al.  Cytomegalovirus after heart transplantation. Risk factors for infection and death: a multiinstitutional study. The Cardiac Transplant Research Database Group. , 1994, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[10]  M. Stegall,et al.  Two hundred consecutive simultaneous pancreas-kidney transplants with bladder drainage. , 1993, Surgery.

[11]  R. Stratta,et al.  THE UTILITY OF URINE CYTOLOGY IN THE DIAGNOSIS OF ALLOGRAFT REJECTION AFTER COMBINED PANCREAS‐KIDNEY TRANSPLANTATION , 1993, Transplantation.

[12]  R. Nakhleh,et al.  Biopsies from pancreas allografts at time of dysfunction: pathologic comparison of allografts which ultimately failed versus those which continued to function. , 1993, Transplantation proceedings.

[13]  H. Tilg,et al.  Pancreatic juice neopterin excretion--a reliable marker of pancreas allograft rejection. , 1992, Transplantation proceedings.

[14]  H. Tilg,et al.  Urinary and pancreatic juice neopterin excretion after combined pancreas-kidney transplantation. , 1992, Transplantation.

[15]  R. Margreiter,et al.  MORPHOLOGY OF ACUTE REJECTION AND CORRESPONDING CYTOLOGICAL FINDINGS IN EXOCRINE SECRETION AFTER PANCREAS TRANSPLANTATION IN THE RAT , 1991, Transplantation.

[16]  R. Margreiter,et al.  Histological features of acute pancreatic allograft rejection after pancreaticoduodenal transplantation in the rat , 1991, Transplant international : official journal of the European Society for Organ Transplantation.

[17]  R. Margreiter,et al.  A technique of pancreas transplantation in the rat securing pancreatic juice for monitoring , 1990, Transplant international : official journal of the European Society for Organ Transplantation.

[18]  R. Margreiter,et al.  Pancreatic juice cytology in the monitoring of pancreas allografts. , 1989, Transplantation.

[19]  W. Hawthorne,et al.  Percutaneous fine needle aspiration biopsy of canine pancreas allograft provides diagnosis of treatable rejection. , 1989, The Journal of surgical research.

[20]  F. Reinholt,et al.  Pancreatic juice cytology in the diagnosis of pancreatic graft rejection , 1988 .

[21]  R. Margreiter,et al.  Pancreas transplantation--the Innsbruck experience. , 1987, Transplantation proceedings.

[22]  D. Niederwieser,et al.  Monitoring of the pancreatic allograft by analysis of exocrine secretion. , 1987, Transplantation proceedings.